Glenmark receives a trio of FDA approvals

NEW YORK The Food and Drug Administration has approved Glenmark Generics’ application to market trandolapril tablets, a generic version of Abbott Laboratories’ Mavik.

Glenmark, based in India, will market the blood-pressure drug in doses 1 mg, 2 mg and 4 mg doses. Eight other companies will also market generic versions of Mavik.

Glenmark has also received approval for Schering-Plough’s Elocon ointment and cream (mometasone furoate), which treats skin inflammation, and Bristol-Myers Squibb’s diabetes drug Glucophage (metformin HCl).

Mavik had sales of more than $23 million in the 12 months ending in March, according to IMS Health data.